We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biogen has launched a phase 3 trial of its monoclonal antibody, BIIB059, a potential blockbuster that has shown promise for treating individuals suffering from lupus, a chronic and debilitating autoimmune disease. Read More
Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz (tofacitinib) reduced the incidence of death or respiratory failure among hospitalized patients with COVID-19 pneumonia in a Brazilian study. Read More
CureVac’s much-anticipated messenger RNA-based COVID-19 vaccine, CVnCoV, was only 47 percent effective at preventing symptomatic disease in a sizable trial at its interim analysis, missing success criteria. Meantime, Europe has pre-ordered 225 million doses of the vaccine, which may not achieve regulatory authorization. Read More
Regeneron’s antibody cocktail, REGEN-COV, has demonstrated a reduced risk of death for COVID-19 patients in one arm of the UK’s Recovery trial that is investigating multiple potential COVID-19 treatments. Read More
AstraZeneca’s monoclonal antibody cocktail, AZD7442, failed to prevent symptomatic COVID-19 infection in a late-stage study of individuals recently exposed to the SARS-CoV-2 virus. Read More
The data provide “the first comparative evidence” that the Imbruvica combination has the potential to extend time to disease progression vs. standard therapy,” the trial’s lead investigator said. Read More
Novavax said it plans to file for FDA Emergency Use Authorization (EUA) of its two-dose COVID-19 vaccine in the third quarter, supported by the strong efficacy data from its late-stage trial in which the recombinant DNA-based vaccine proved 100 percent effective in preventing moderate and severe disease, and more than 90 percent effective at preventing symptomatic infections. Read More